Short Interest in International Stem Cell Corp. (OTCMKTS:ISCO) Decreases By 94.3%

International Stem Cell Corp. (OTCMKTS:ISCO) saw a significant drop in short interest in December. As of December 31st, there was short interest totaling 32 shares, a drop of 94.3% from the December 15th total of 563 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average trading volume of 26,639 shares, the short-interest ratio is currently 0.0 days. Based on an average trading volume of 26,639 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the company’s shares are short sold.

International Stem Cell Trading Down 7.7%

Shares of ISCO stock traded down $0.01 during trading hours on Monday, reaching $0.12. 400 shares of the stock were exchanged, compared to its average volume of 950. The firm has a market capitalization of $960,000.00, a price-to-earnings ratio of -6.00 and a beta of 0.18. The company’s 50-day moving average price is $0.14 and its 200-day moving average price is $0.15. International Stem Cell has a 12-month low of $0.08 and a 12-month high of $0.27.

About International Stem Cell

International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.

In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.